BCLI vs. AADI, PRLD, LIAN, GRCE, NBRV, XCUR, SCLX, MURA, OSTX, and LTRN
Should you be buying Brainstorm Cell Therapeutics stock or one of its competitors? The main competitors of Brainstorm Cell Therapeutics include Aadi Bioscience (AADI), Prelude Therapeutics (PRLD), LianBio (LIAN), Grace Therapeutics (GRCE), Nabriva Therapeutics (NBRV), Exicure (XCUR), Scilex (SCLX), Mural Oncology (MURA), OS Therapies (OSTX), and Lantern Pharma (LTRN). These companies are all part of the "pharmaceutical products" industry.
Brainstorm Cell Therapeutics vs. Its Competitors
Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.
Brainstorm Cell Therapeutics has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Brainstorm Cell Therapeutics' return on equity of 0.00% beat Aadi Bioscience's return on equity.
In the previous week, Brainstorm Cell Therapeutics had 5 more articles in the media than Aadi Bioscience. MarketBeat recorded 5 mentions for Brainstorm Cell Therapeutics and 0 mentions for Aadi Bioscience. Aadi Bioscience's average media sentiment score of 0.00 beat Brainstorm Cell Therapeutics' score of -0.02 indicating that Aadi Bioscience is being referred to more favorably in the news media.
Aadi Bioscience has a consensus target price of $1.67, indicating a potential downside of 14.09%. Given Aadi Bioscience's higher possible upside, analysts clearly believe Aadi Bioscience is more favorable than Brainstorm Cell Therapeutics.
Brainstorm Cell Therapeutics has higher earnings, but lower revenue than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.
Brainstorm Cell Therapeutics has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500. Comparatively, Aadi Bioscience has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500.
14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are owned by institutional investors. 11.2% of Brainstorm Cell Therapeutics shares are owned by company insiders. Comparatively, 37.3% of Aadi Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Aadi Bioscience beats Brainstorm Cell Therapeutics on 8 of the 13 factors compared between the two stocks.
Get Brainstorm Cell Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BCLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Brainstorm Cell Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:BCLI) was last updated on 7/25/2025 by MarketBeat.com Staff
Free BCLI Stock Alerts